Share on StockTwits

Repros Therapeutics (NASDAQ:RPRX) CFO Katherine Anderson bought 2,000 shares of Repros Therapeutics stock on the open market in a transaction dated Thursday, August 14th. The stock was purchased at an average price of $13.85 per share, with a total value of $27,700.00. Following the completion of the purchase, the chief financial officer now directly owns 8,375 shares of the company’s stock, valued at approximately $115,994. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Repros Therapeutics (NASDAQ:RPRX) opened at 14.56 on Monday. Repros Therapeutics has a 1-year low of $12.61 and a 1-year high of $29.79. The stock has a 50-day moving average of $15.16 and a 200-day moving average of $16.81. The company’s market cap is $336.5 million.

Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.38) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.37) by $0.01. On average, analysts predict that Repros Therapeutics will post $-1.53 earnings per share for the current fiscal year.

Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.